γδ T 细胞调节小细胞肺癌中的抗肿瘤免疫
γδ T cells modulate anti-tumor immunity in small cell lung cancer.
我们的发现表明,活化的γδ T细胞可能是SCLC治疗的有价值靶点。
英文原题:TIGIT-expressing zoledronate-specific γδ T cells display enhanced antitumor activity.
人γδ T细胞通过其快速激活和细胞因子分泌在肿瘤免疫监视中发挥关键作用,并在透明细胞肾细胞癌(ccRCC)的过继免疫治疗中受到广泛关注。
人γδ T细胞通过其迅速激活和细胞因子分泌在肿瘤免疫监视中发挥关键作用,并在透明细胞肾细胞癌(ccRCC)的过继免疫治疗中受到广泛关注。然而,在ccRCC中治疗效果有限。因此,现在至关重要的是改进基于γδ T细胞的治疗策略,尤其是鉴定功能性γδ T细胞亚群。在本研究中,我们旨在鉴定可能对ccRCC具有增强反应的γδ T细胞。生物信息学分析显示,T细胞免疫球蛋白和免疫受体酪氨酸抑制基序结构域(TIGIT)高表达的ccRCC患者具有更高水平的效应分子。然后,我们通过唑来膦酸(ZOL)刺激检测了6例ccRCC患者和14名健康受试者中TIGIT + γδ T细胞百分比的变化。结果表明,TIGIT + γδ T细胞的百分比与早期激活阶段的活化γδ T细胞呈正相关。进一步研究表明,与TIGIT - γδ T细胞相比,TIGIT + γδ T细胞表现出增强的激活,包含更多终末分化效应γδ T细胞并产生更高水平的细胞因子。最后,我们研究了其功能,发现TIGIT + γδ T细胞在受到肿瘤细胞挑战时表现出更强的肿瘤反应性和更高的细胞毒性。上述结果提示,TIGIT + γδ T细胞是ZOL识别和肿瘤细胞挑战中的主要效应细胞。本研究结果为未来TIGIT + γδ T细胞的功能研究奠定了基础,并为ccRCC的免疫治疗提供了一种有前景的方法。
Human γδ T cells hold a pivotal role in tumor immunosurveillance through their prompt activation and cytokine secretion and have received much attention in adoptive immunotherapy of clear cell renal cell carcinoma (ccRCC). However, the therapeutic effects are limited in ccRCC. Therefore, it is now critical to improve therapeutic strategies based on γδ T cells, especially identification of functional γδ T cell subsets. In this study, we aimed to identify γδ T cells that might have enhanced responses against ccRCC. Bioinformatic analysis showed that ccRCC patients with high T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) expression had higher levels of effector molecules. Then, we examined the changes in the TIGIT + γδ T cell percentages of 6 ccRCC patients and 14 healthy subjects through zoledronate (ZOL) stimulation. Results indicated that percentages of TIGIT + γδ T cells were positively correlated with activated γδ T cells in early activation stage. Further study demonstrated that TIGIT + γδ T cells exhibited enhanced activation, contained more terminally differentiated effector γδ T cells and produced higher cytokine compared with TIGIT - γδ T cells. Finally, we investigated the functions and found that TIGIT + γδ T cells exhibited stronger tumor reactivities and higher cytotoxicity when challenged by tumor cells. Above results imply that TIGIT + γδ T cells are the main effectors in ZOL recognition and tumor cells challenging. The results of the present study serve as basis for future functional studies on TIGIT + γδ T cells and provide a promising approach of immunotherapy in ccRCC.
MEMBER ACCOUNT
登录成功会直接打开下一页。